Results 171 to 180 of about 48,143 (212)

Phosphodiesterase inhibitors as therapeutics for traumatic brain injury. [PDF]

Curr Pharm Des, 2015
Titus DJ, Oliva AA, Wilson NM, Atkins CM.   +3 more
europepmc   +1 more source

A cAMP-Specific Phosphodiesterase Inhibitor Preserves the Motility of Washed Human Sperm

, 1997
J Fisch
openalex   +1 more source

Antiplatelet and cardiovascular effects of NM-702, a novel multiple inhibitor of cyclic-nudeotide phosphodiesterases and thromboxane A synthase.

, 1996
Nohutomo Tsuruzoe, Norimasa Shudo, Kanako Takahashi, Naoki Fujikura, Masakuni Nishikawa, Takeshi Uchida, Sakuya Tanaka   +6 more
openalex   +1 more source

Emerging antihypertensive therapies and cardiovascular, kidney, and metabolic outcomes: a Mendelian randomization study. [PDF]

Eur Heart J Cardiovasc Pharmacother
Le NN, Tran TQB, McClure J, Gill D, Padmanabhan S.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Electrophysiology of phosphodiesterase inhibitors

The American Journal of Cardiology, 1989
Phosphodiesterase inhibitors appear to uniformly enhance atrioventricular node conduction, although milrinone seems to have the least effect. Except for digoxin, this effect on atrioventricular node conduction is similar to that noted with other inotropic agents.
Richard A. Goldstein, Gerald V. Naccarelli   +1 more
openaire   +3 more sources

Phosphodiesterase inhibitors and the eye

Clinical & Experimental Ophthalmology, 2009
AbstractPhosphodiesterase type 5 (PDE5) inhibitors are effective oral treatments for erectile dysfunction and have become one of the most widely prescribed medications worldwide. The mechanism of action is to reduce the degradation of cyclic GMP (cGMP) potentiating the effect of nitric oxide in the corpus cavernosum and allowing erectile function to ...
Nathan M. Kerr, Helen V. Danesh-Meyer
openaire   +2 more sources

In Defense of Phosphodiesterase 5 Inhibitors

JAMA Ophthalmology, 2022
Not ...
Belladelli, Federico, Del Giudice, Francesco, Eisenberg, Michael L   +2 more
openaire   +3 more sources

Phosphodiesterase 4 inhibitors

Journal of the American Academy of Dermatology, 2018
Historically, drugs available for treating atopic dermatitis (AD) have been limited to topical corticosteroids and topical calcineurin inhibitors, with systemic immunosuppressants and phototherapy reserved for severe AD. Despite their efficacy and infrequent adverse events, phobia about the use of topical steroids and calcineurin inhibitors has limited
Rema Zebda, Amy S. Paller
openaire   +3 more sources